MaaT Pharma announced on Tuesday that it had completed patient enrolment in its Phase 2a clinical trial evaluating MaaT013, its most advanced drug candidate, in melanoma.

A total of 70 patients have been enrolled at five different centers in France in this randomized controlled trial, which began in April 2022.

Sponsored by AP-HP and conducted in collaboration with Inrae and Institut Gustave Roussy, the trial aims to evaluate the compound's efficacy alongside the immune checkpoint inhibitors Yervoy and Opdivo, belonging to the American company Bristol Myers Squibb.

As part of the study, the pharmaceutical company has supplied the drug candidate MaaT013 and the placebo, and will carry out analyses of patients' microbiota using its proprietary 'gutPrint' platform.

Following this milestone, submission of the study results to a scientific journal is scheduled for the last quarter of 2024 or the first quarter of 2025.

Copyright (c) 2024 CercleFinance.com. All rights reserved.